Hot Features
Premium
Level up your trading with our powerful tools and real-time insights all in one place.
Period:
Draw Mode:
| Volume | 403,437 |
|
|||||
| News | - | ||||||
| Day High | 13.72 | Low High |
|||||
| Day Low | 12.82 | ||||||
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Kyverna Therapeutics Inc | KYTX | NASDAQ | Common Stock |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.23 | 1.77% | 13.23 | 19:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 13.20 | 12.82 | 13.72 | 13.23 | 13.00 |
| Trades | Shares Traded | VWAP | Financial Volume | Average Volume | 52 Week Range |
|---|---|---|---|---|---|
| 6,228 | 403,437 | US$ 13.07 | US$ 5,272,597 | - | 12.15 - 35.01 |
| Last Trade | Type | Quantity | Price | Currency |
|---|---|---|---|---|
| 15:00:19 | priorref | 623 | US$ 13.23 | USD |
Kyverna Therapeutics Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 539.27M | 40.82M | - | 0 | -60.37M | -1.48 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Kyverna Therapeutics News
| Date | Time | Source | News Article |
|---|---|---|---|
| 5/14/2024 | 15:29 | Edgar (US Regulatory) | Form 10-Q - Quarterly report [Sections 13 or 15(d)] |
| 5/14/2024 | 15:25 | Edgar (US Regulatory) | Form 8-K - Current report |
| 5/14/2024 | 15:05 | PR Newswire (US) | Kyverna Therapeutics Provides Business Update and Reports.. |
| 4/11/2024 | 16:01 | PR Newswire (US) | Kyverna Therapeutics to attend the 2024 American Academy of.. |
| 3/29/2024 | 13:59 | PR Newswire (US) | First-in-Disease Use of Kyverna Therapeutics' KYV-101 in.. |
| 3/26/2024 | 15:05 | PR Newswire (US) | Kyverna Therapeutics Provides Business Update and Reports.. |
| 3/07/2024 | 18:26 | PR Newswire (US) | Kyverna Therapeutics and Stanford University Agree to.. |
| 2/12/2024 | 15:39 | PR Newswire (US) | Kyverna Therapeutics Announces Closing of Initial Public.. |
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical KYTX Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 14.22 | 14.29 | 12.15 | 13.17 | 234,738 | -0.99 | -6.96% |
| 1 Month | 14.86 | 17.55 | 12.15 | 14.71 | 342,770 | -1.63 | -10.97% |
| 3 Months | 28.65 | 30.60 | 12.15 | 20.44 | 386,251 | -15.42 | -53.82% |
| 6 Months | 34.25 | 35.01 | 12.15 | 22.87 | 415,980 | -21.02 | -61.37% |
| 1 Year | 34.25 | 35.01 | 12.15 | 22.87 | 415,980 | -21.02 | -61.37% |
| 3 Years | 34.25 | 35.01 | 12.15 | 22.87 | 415,980 | -21.02 | -61.37% |
| 5 Years | 34.25 | 35.01 | 12.15 | 22.87 | 415,980 | -21.02 | -61.37% |
Kyverna Therapeutics Description
| Kyverna Therapeutics is a cell therapy company engineering a new class of therapies for autoimmune and inflammatory diseases. The Kyverna therapeutic platform combines advanced T-cell engineering and synthetic biology technologies to suppress and eliminate the autoreactive immune cells at the origin of autoimmune and inflammatory diseases. Kyverna¿s pipeline includes next-generation chimeric antigen receptor T-cell (CAR T) therapies in both autologous and allogeneic formats with properties well suited for use in B cell-driven autoimmune diseases. |
